These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24125107)

  • 1. Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the heart failure with preserved ejection fraction (HFPEF) anemia trial.
    Borovka M; Teruya S; Alvarez J; Helmke S; Maurer MS
    J Card Fail; 2013 Oct; 19(10):685-91. PubMed ID: 24125107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy.
    Maurer MS; Teruya S; Chakraborty B; Helmke S; Mancini D
    Circ Heart Fail; 2013 Mar; 6(2):254-63. PubMed ID: 23258574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial.
    Green P; Babu BA; Teruya S; Helmke S; Prince M; Maurer MS
    Congest Heart Fail; 2013; 19(4):172-9. PubMed ID: 23517485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction.
    Altincatal A; Macarthur RB; Teruya S; Helmke S; Maurer MS
    Cardiovasc Ther; 2013 Apr; 31(2):92-9. PubMed ID: 21884028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractions.
    Abramov D; Cohen RS; Katz SD; Mancini D; Maurer MS
    Am J Cardiol; 2008 Oct; 102(8):1069-72. PubMed ID: 18929711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction.
    Vullaganti S; Goldsmith J; Teruya S; Alvarez J; Helmke S; Maurer MS
    J Geriatr Cardiol; 2014 Jun; 11(2):100-5. PubMed ID: 25009558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK; Anand IS; Abraham WT; Fonarow GC; Greenberg B; Krum H; Massie BM; Wasserman SM; Trotman ML; Sun Y; Knusel B; Armstrong P;
    Circulation; 2008 Jan; 117(4):526-35. PubMed ID: 18195176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
    Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure.
    Nijst P; Verbrugge FH; Bertrand PB; Martens P; Dupont M; Drieskens O; Penders J; Tang WH; Mullens W
    J Card Fail; 2017 Feb; 23(2):138-144. PubMed ID: 27561853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
    Crouch Z; DeSantis ER
    Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
    Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
    J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.
    Mancini DM; Katz SD; Lang CC; LaManca J; Hudaihed A; Androne AS
    Circulation; 2003 Jan; 107(2):294-9. PubMed ID: 12538431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of epoetin alfa in critically ill patients.
    Corwin HL; Gettinger A; Fabian TC; May A; Pearl RG; Heard S; An R; Bowers PJ; Burton P; Klausner MA; Corwin MJ;
    N Engl J Med; 2007 Sep; 357(10):965-76. PubMed ID: 17804841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
    BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
    Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volume Overload Profiles in Patients With Preserved and Reduced Ejection Fraction Chronic Heart Failure: Are There Differences? A Pilot Study.
    Miller WL; Mullan BP
    JACC Heart Fail; 2016 Jun; 4(6):453-9. PubMed ID: 26970830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.